131 related articles for article (PubMed ID: 35317944)
21. Morphometric, Developmental, and Anti-Inflammatory Effects of Transamniotic Stem Cell Therapy (TRASCET) on the Fetal Heart and Lungs in a Model of Intrauterine Growth Restriction.
Whitlock AE; Moskowitzova K; Kycia I; Zurakowski D; Fauza DO
Stem Cells Dev; 2023 Aug; 32(15-16):484-490. PubMed ID: 37358376
[TBL] [Abstract][Full Text] [Related]
22. Initial Mechanistic Screening of Transamniotic Stem Cell Therapy in the Rodent Model of Spina Bifida: Host Bone Marrow and Paracrine Activity.
Lazow SP; Tracy SA; Chalphin AV; Kycia I; Zurakowski D; Fauza DO
Fetal Diagn Ther; 2020; 47(12):902-911. PubMed ID: 32877907
[TBL] [Abstract][Full Text] [Related]
23. Transamniotic stem cell therapy (TRASCET): An emerging minimally invasive strategy for intrauterine stem cell delivery.
Moskowitzova K; Fauza DO
Semin Perinatol; 2023 Apr; 47(3):151728. PubMed ID: 36990923
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of transamniotic stem cell therapy for spina bifida by genetic engineering of donor mesenchymal stem cells with an Fgf2 transgene.
Lazow SP; Labuz DF; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2021 Jun; 56(6):1226-1232. PubMed ID: 33771369
[TBL] [Abstract][Full Text] [Related]
25. Intrauterine Growth Restriction (IUGR) as a potential target for transamniotic stem cell therapy.
Labuz DF; Whitlock AE; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2022 Jun; 57(6):999-1003. PubMed ID: 35277250
[TBL] [Abstract][Full Text] [Related]
26. A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida.
Feng C; D Graham C; Connors JP; Brazzo J; Zurakowski D; Fauza DO
J Pediatr Surg; 2016 Jun; 51(6):1010-3. PubMed ID: 27013425
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effects on Fetal Hematopoiesis and Placental Inflammation From Mesenchymal and Hematopoietic Stem Cells as Agents of Transamniotic Stem Cell Therapy (TRASCET) in a Syngeneic Model of Intrauterine Growth Restriction.
Moskowitzova K; Naus AE; Kycia I; Dang TT; Shroff YV; Bletsas E; Mullin K; Zurakowski D; Fauza DO
J Pediatr Surg; 2024 Jul; 59(7):1277-1281. PubMed ID: 38575446
[TBL] [Abstract][Full Text] [Related]
28. Transamniotic Stem Cell Therapy for Experimental Congenital Diaphragmatic Hernia: Structural, Transcriptional, and Cell Kinetics Analyses in the Nitrofen Model.
Chalphin AV; Lazow SP; Labuz DF; Tracy SA; Kycia I; Zurakowski D; Fauza DO
Fetal Diagn Ther; 2021; 48(5):381-391. PubMed ID: 33853064
[TBL] [Abstract][Full Text] [Related]
29. Fetal therapy with rhIGF-1 in a rabbit model of intrauterine growth retardation.
Skarsgard ED; Amii LA; Dimmitt RA; Sakamoto G; Brindle ME; Moss RL
J Surg Res; 2001 Jul; 99(1):142-6. PubMed ID: 11421616
[TBL] [Abstract][Full Text] [Related]
30. Partial or complete coverage of experimental spina bifida by simple intra-amniotic injection of concentrated amniotic mesenchymal stem cells.
Dionigi B; Ahmed A; Brazzo J; Connors JP; Zurakowski D; Fauza DO
J Pediatr Surg; 2015 Jan; 50(1):69-73. PubMed ID: 25598096
[TBL] [Abstract][Full Text] [Related]
31. Congenital diaphragmatic hernia as a potential target for transamniotic stem cell therapy.
Chalphin AV; Tracy SA; Lazow SP; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Feb; 55(2):249-252. PubMed ID: 31753611
[TBL] [Abstract][Full Text] [Related]
32. Transamniotic stem cell therapy (TRASCET) mitigates bowel damage in a model of gastroschisis.
Feng C; Graham CD; Connors JP; Brazzo J; Pan AH; Hamilton JR; Zurakowski D; Fauza DO
J Pediatr Surg; 2016 Jan; 51(1):56-61. PubMed ID: 26548631
[TBL] [Abstract][Full Text] [Related]
33. Strategies for intra-amniotic administration of fetal therapy in a rabbit model of intrauterine growth restriction.
Kinoshita M; Crispi F; Loreiro C; Gratacós E; Illa M; Zamora M
Exp Biol Med (Maywood); 2021 Jul; 246(14):1668-1679. PubMed ID: 33794699
[TBL] [Abstract][Full Text] [Related]
34. Transamniotic stem cell therapy (TRASCET) in a leporine model of gastroschisis.
Feng C; Graham CD; Shieh HF; Brazzo JA; Connors JP; Rohrer L; Papadakis A; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Jan; 52(1):30-34. PubMed ID: 27836365
[TBL] [Abstract][Full Text] [Related]
35. Transamniotic fetal feeding: enhancement of growth in a rabbit model of intrauterine growth retardation.
Buchmiller TL; Kim CS; Chopourian HL; Fonkalsrud EW
Surgery; 1994 Jul; 116(1):36-41. PubMed ID: 8023266
[TBL] [Abstract][Full Text] [Related]
36. Successful use of an artificial placenta-based life support system to treat extremely preterm ovine fetuses compromised by intrauterine inflammation.
Usuda H; Watanabe S; Saito M; Ikeda H; Koshinami S; Sato S; Musk GC; Fee E; Carter S; Kumagai Y; Takahashi T; Takahashi Y; Kawamura S; Hanita T; Kure S; Yaegashi N; Newnham JP; Kemp MW
Am J Obstet Gynecol; 2020 Nov; 223(5):755.e1-755.e20. PubMed ID: 32380175
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone-related protein(1-34) in gestational fluids and release from human gestational tissues.
Farrugia W; Ho PW; Rice GE; Moseley JM; Permezel M; Wlodek ME
J Endocrinol; 2000 Jun; 165(3):657-62. PubMed ID: 10828849
[TBL] [Abstract][Full Text] [Related]
38. Transamniotic Stem Cell Therapy (TRASCET) Modulates Uterine Natural Killer Cell (uNK) Activity in the Hypoxia Model of Intrauterine Growth Restriction (IUGR).
Whitlock A; Moskowitzova K; Kycia I; Zurakowski D; Fauza DO
Stem Cells Dev; 2024 Jun; ():. PubMed ID: 38874223
[TBL] [Abstract][Full Text] [Related]
39. The availability of cortisol in amniotic fluid to the fetus and chorionic and amniotic membranes.
Carson GD; Bolla JD; Challis JR
Endocrinology; 1979 Apr; 104(4):1053-8. PubMed ID: 436746
[TBL] [Abstract][Full Text] [Related]
40. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta.
In 't Anker PS; Scherjon SA; Kleijburg-van der Keur C; de Groot-Swings GM; Claas FH; Fibbe WE; Kanhai HH
Stem Cells; 2004; 22(7):1338-45. PubMed ID: 15579651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
